drugset / Trial / NCT04501770
A Study of M802 (HER2 and CD3) in HER2-Positive Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and tolerability of different doses of M802 in patients with HER2-positive advanced solid tumors, and to determine the dose limiting toxicity (DLT) and the maximum tolerated dose (MTD) so as to provide basis for the recommended phase 2 dose (RP2D).
Timeline
- Start
- 2018-09-27
- Primary completion
- 2022-05-06
- Completion
- 2022-09-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | M802 | Monoclonal antibody | 5 ug | Intravenous |
| Subject | M802 | Monoclonal antibody | 10 ug | Intravenous |
| Subject | M802 | Monoclonal antibody | 20 ug | Intravenous |
| Subject | M802 | Monoclonal antibody | 50 ug | Intravenous |
| Subject | M802 | Monoclonal antibody | 100 ug | Intravenous |
| Subject | M802 | Monoclonal antibody | 150 ug | Intravenous |
| Subject | M802 | Monoclonal antibody | 225 ug | Intravenous |
| Subject | M802 | Monoclonal antibody | 300 ug | Intravenous |
Indications
No indication recorded.